Organ Transplantation
Conditions
Keywords
Remote Ischemic Preconditioning, Brain death organ donors, Delayed graft function, Donor management, Pulsatile perfusion
Brief summary
The purpose of this study is to determine whether application of lower limb remote ischemic preconditioning (RIPC) after determination of brain death improves donor stability, organ quality, organ yield, and early post transplant clinical outcomes. Neurological death donors will be stratified into standard and extended criteria donors (SCD/ECD) and randomized in a 1:1 fashion to RIPC or No intervention. The primary outcome is the number of organs recovered per donor. Secondary outcomes include donor hemodynamic state, donor organ-specific function parameters, pulsatile perfusion parameters, number of organs transplanted per donor, recipient hospital free survival and delayed graft function of kidneys. The sample size is powered to detect a difference of 0.44 organs recovered.
Detailed description
Study Design and Participants The RIPNOD trial was conducted from July 2011 to July 2014 as a prospective randomized trial in two OPOs (in New Jersey and in Texas) in the U.S. The funding organization, institutional review boards and the physician committees of the two organ procurement organizations (OPOs) approved the study. Exemptions for consent from potential recipients and for a data and safety monitoring board were granted. Consent for research was obtained from the donor's next of kin by OPO staff unless a 'first-person' consent existed. The study population consisted of neurological death organ donors. Eligible donors were age \> 6 years, in whom death declaration was either imminent or completed, and organ recovery was not expected within 6 hours of enrollment. Donors with severe trauma to lower extremity or on sulfonylurea agents were excluded (Trial Protocol in Supplement). Procedures Randomization (1:1) to No RIPC or RIPC groups in standard and extended criteria donors (SCD and ECD) strata occurred based on a computer-generated random table of numbers. In Texas, field coordinators performed the randomization through a website and administered the intervention. In New Jersey, research staff performed all trial activities and randomized using opaque, sealed envelopes. Organ recovery teams were informed of the study and sometimes knew of the group assignment. The recipient care teams and recipients were not aware of the group assignment. The intervention consisted of four cycles of inflation of a tourniquet around mid-thigh to 250 mm Hg for 5 minutes followed by 5 minutes of deflation. The initial intervention occurred in the right thigh as early as possible after declaration of death. The second intervention occurred in the left thigh 24 hours after the initial intervention, or immediately before recovery, if this was earlier. Videoconferences between the two sites helped standardize the intervention before the trial commenced. All decisions regarding donor management, organ recovery, machine perfusion of kidneys, transplantation of organs and care after transplantation were independent of the research teams. Outcomes and Data Collection The primary outcome was the total number of organs recovered per donor. Secondary outcomes were number of organs transplanted per donor, and changes from baseline to terminal (before aortic cross clamp) in vasopressor support, serum lactate, creatinine clearance, left ventricular ejection fraction, serum troponins, partial pressure of arterial oxygen: fraction inspired oxygen (P:F) ratio, dynamic and static lung compliance, and perfusate flow and resistance in machine perfused kidneys, delayed graft function (DGF) in transplanted kidneys and six-month hospital free survival in all recipients. A score quantified vasopressor support.14 All laboratory tests were performed at donor hospitals. Cockcroft-Gault equation was used to calculate creatinine clearance.15 Donor hospital cardiologists estimated the ventricular ejection fraction in transthoracic echocardiograms. OPO policies dictated machine perfusion of kidneys; perfusion, occurred at a central location in each OPO. Delayed graft function was defined as dialysis in the first week after transplant. Six month hospital-free survival was defined as the number of days recipients survived following the initial discharge after the transplant. All donor data were obtained prospectively from OPO records. Data after transplantation were obtained from the Scientific Registry of Transplant Recipients (SRTR). The SRTR data system includes data on all donors, waitlist candidates, and transplant recipients in the United States, submitted by members of the Organ Procurement and Transplantation Network (OPTN). The Health Resources and Services Administration (HRSA), U.S. Department of Health and Human Services provides oversight to the activities of the OPTN and SRTR contractors. Sample Size A sample size of 150 donors in each arm was estimated to provide 80% power to detect a difference of 0.44 of an organ recovered and 0.48 of an organ transplanted per donor. The difference criterion was chosen based on published results achieved with hormonal resuscitation in organ donors. 6 Pooled standard deviations (organs recovered: 1.35; organs transplanted: 1.5) from data of two OPOs were used. Statistical Analyses Intention to treat principle was used in all analyses. Discrete descriptive data are reported as counts and percent and continuous data as means (sd) or medians (interquartile range). Continuous variables were compared using either t, or equivalent non-parametric tests. Categorical variables were compared using chi square tests. Multivariate modeling with backward elimination - linear ones to model RIPC on recovery and transplantation of all (0-8) and abdominal organs (0-5) per donor, and logistic ones to model recovery/transplantation of \> 1 thoracic organ per donor and DGF - was performed. Because only seven fewer thoracic organs were transplanted than recovered the model for organs transplanted was used to analyze both outcomes. Donor characteristics of age, sex, race, cause of death, BMI, comorbidities (hypertension, diabetes, alcohol use, and hepatitis C), treatments (insulin, diuretics and steroids) and laboratory parameters (serum creatinine and P:F ratio) and OPO site were predictor variables in organ yield models. Donor age or stratum, cold ischemia, number of human leukocyte antigen mismatches and recipients' characteristics of age, sex, race, BMI, diabetes, hypertension, etiology of renal failure, panel reactive antibody and OPO site were predictor variables in models of DGF. For linear regression models, adjusted R2 was computed and residuals were assessed for normality; the C statistic was used to assess goodness of the fit for logistic regression. Statistical significance was set at p\<0.05. Post Hoc Analyses Rates of acute rejection of kidney during the first six months were compared between the two groups using chi square tests. Kaplan-Meier estimates and log rank tests were used to compare unadjusted outcomes of graft and patient survival at 6, 12 and 24 months. In heart, lung and liver recipients, retransplantation or death was defined as graft loss. In all other organs graft loss was death-censored. Cox proportional hazards models were used to estimate the effect of RIPC on the adjusted hazard ratio for six-month graft loss after controlling for OPO site, donor age or stratum and sex, cold ischemia time, number of antigen mismatches, organ transplanted, and recipient age, sex, race, BMI, diabetes and hypertension.
Interventions
Remote Ischemic Preconditioning (RIPC) by Inflation of Pneumatic Tourniquet. The intervention will consist of tourniquet inflation on the mid-thigh for 5 minutes, followed by a deflation period of 5 minutes for a total of 4 cycles. The intervention will take place at two time points: First, after determination of brain death and consent for organ donation and again upon incision for organ recovery. The second intervention will occur in a manner identical to the first intervention but in the opposite limb.
Sponsors
Study design
Eligibility
Inclusion criteria
1. Neurological death donors in whom brain death determination is imminent 2. First person consent or next of kin consent for research 3. Donors \>=6 years of age 4. Organ recovery not expected within 6 hours of consent. 5. Both sexes and ethnicities.
Exclusion criteria
1. Donation after cardiac death donors (DCD) 2. Live organ donors 3. No first person consent and next of kin decline research consent 4. Donor Age \< 6 years 5. Lower extremity trauma or recent amputation 6. Tissue only donors
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Organs Recovered Per Donor | At time of organ recovery, up to 1 day | Number of organs recovered per organ donor |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Vasopressor Score | Vasopressor score was determined before aortic cross clamp minus the value prior to the first intervention, an average of 19 hours | Changes in the following: Vasopressor usage, serum Lactate, Creatinine clearance, arterial oxygen pressure:fraction of inspired oxygen (P:F) ratios, Lung Compliance, Cardiac biomarkers, ejection fraction (EF) from 2-dimensional Echocardiogram. Here we will present data for the change in vasopressor use evaluated using a vasopressor score. A numerical score calculated for number and dose of Vasopressors in use. The score is calculated using the following formula (from Zuppa AF et. al.CRIT CARE MED 2004 Vol. 32 p 2318-2322): Vasopressor Score= (dopamine dose\[y=ug/kg/min x 1\]) + (dobutamine dose \[ug/kg/min\] x 1) + (epinephrine dose \[ug/kg/min\] x100) + (norepinephrine dose \[ug/kg/min\] x 100) + (phenylephrine dose \[ug/kg/min\] x 100). The range for our study was 0-4900 with higher doses indicating higher vasopressor use in the donor. |
| Change in Serum Lactate | Subjects will be followed from admission to explantation, an average of 4.5 days | Change in serum lactate levels (mg/dL) from before intervention to the final value |
| Change in Creatinine Clearance | Subjects will be followed from admission to explantation, an average of 4.5 days | Change in creatinine clearance (mL/min by Cockcroft-Gault method) from before intervention to terminal value |
| Change in P:F Ratio | Subjects will be followed from admission to explantation, an average of 4.5 days | Change in ratio of arterial oxygen pressure:fraction inspired oxygen ratio from before intervention to terminal value |
| Change in Dynamic Compliance | Subjects will be followed from admission to explantation, an average of 4.5 days | Change in dynamic compliance of the lung from before intervention to terminal value Cdyn = Dynamic compliance; Vt = tidal volume; PIP = Peak inspiratory pressure (the maximum pressure during inspiration); PEEP = Positive End Expiratory Pressure: Cdyn= Vt/PIP - PEEP |
| Number of Organs Transplanted Per Donor | Within 24 hours of organ recovery | Number of organs transplanted from each organ donor |
| Pulsatile Perfusion Flow | Up to 24 hours of machine perfusion | Perfusate flow (mL/min) in machine perfused kidneys. |
| Six Month Hospital Free Survival of All Organ Recipients | 6 months post-transplant | Six month hospital-free survival was defined as the number of days recipients survived following the initial discharge after the transplant. |
| Delayed Graft Function (DGF) of Kidney Recipients. | 7 days post-transplant | DGF is defined as the need for dialysis within the first week post transplantation. |
| Pulsatile Perfusion Parameters | Up to 24 hours of machine perfusion | Perfusate resistance (mm Hg/mL/min) in machine perfused kidneys. |
| Change in Troponins | Subjects will be followed from admission to explantation, an average of 4.5 days | Change in serum troponin I (ng/mL) from before intervention to terminal value |
Countries
United States
Participant flow
Recruitment details
The RIPNOD trial was conducted from July 2011 to July 2014 in two organ procurement organizations (OPO) in the U.S. Consent for research was obtained from donors next of kin by the OPO staff unless a 'first person' consent existed.
Participants by arm
| Arm | Count |
|---|---|
| No RIPC The donors assigned to this group will receive standard of care of management of brain death donors in each organ procurement organization. | 166 |
| RIPC The donors assigned to this group would receive two RIPC interventions. The first one would occur immediately after brain death declaration and consent for organ donation. The second one would occur immediately before commencement of organ recovery. At each occasion RIPC would be induced by 4 cycles of mid-thigh inflation of tourniquet for 5 min followed by deflation for 5 minutes.
RIPC (Remote Ischemic Preconditioning): Remote Ischemic Preconditioning (RIPC) by Inflation of Pneumatic Tourniquet. The intervention will consist of tourniquet inflation on the mid-thigh for 5 minutes, followed by a deflation period of 5 minutes for a total of 4 cycles. The intervention will take place at two time points: First, after determination of brain death and consent for organ donation and again upon incision for organ recovery. The second intervention will occur in a manner identical to the first intervention but in the opposite limb. | 155 |
| Total | 321 |
Baseline characteristics
| Characteristic | No RIPC | RIPC | Total |
|---|---|---|---|
| Age, Continuous | 44 years | 42 years | 43 years |
| Age, Customized 11-25 | 24 participants | 34 participants | 58 participants |
| Age, Customized 26-35 | 39 participants | 27 participants | 66 participants |
| Age, Customized 36-45 | 26 participants | 34 participants | 60 participants |
| Age, Customized 46-75 | 77 participants | 60 participants | 137 participants |
| Body Mass Index (BMI) BMI < 30.0 | 126 participants | 104 participants | 230 participants |
| Body Mass Index (BMI) BMI =/> 30.0 | 40 participants | 51 participants | 91 participants |
| Central Line Use No | 45 participants | 39 participants | 84 participants |
| Central Line Use Yes | 121 participants | 116 participants | 237 participants |
| Co-Morbidities Diabetes: No | 147 participants | 134 participants | 281 participants |
| Co-Morbidities Diabetes: Yes | 19 participants | 21 participants | 40 participants |
| Co-Morbidities Hypertension: No | 108 participants | 107 participants | 215 participants |
| Co-Morbidities Hypertension: Yes | 58 participants | 48 participants | 106 participants |
| Co-Morbidities Past or Current Smoker:No | 77 participants | 56 participants | 133 participants |
| Co-Morbidities Past or Current Smoker:Yes | 89 participants | 99 participants | 188 participants |
| Declaration of Death to Initial Intervention, Hours | 5.8 hours | 7.3 hours | 6.5 hours |
| Hepatitis C Antibody No | 159 participants | 139 participants | 298 participants |
| Hepatitis C Antibody Yes | 7 participants | 16 participants | 23 participants |
| Initial Intervention to Cross Clamp Intervention to Cross Clamp: 24.1-39.5 hours | 35 participants | 25 participants | 60 participants |
| Initial Intervention to Cross Clamp Intervention to Cross Clamp: 5.9-24.0 hours | 123 participants | 115 participants | 238 participants |
| Initial Intervention to Cross Clamp Intervention to Cross Clamp: Data not available | 8 participants | 15 participants | 23 participants |
| Insulin Infusion Insulin Infusion: No | 119 participants | 113 participants | 232 participants |
| Insulin Infusion Insulin Infusion: Yes | 47 participants | 42 participants | 89 participants |
| P:F ratio | 249.8 ratio | 244.0 ratio | 248 ratio |
| Race/Ethnicity, Customized African-American | 35 participants | 42 participants | 77 participants |
| Race/Ethnicity, Customized Hispanic | 30 participants | 38 participants | 68 participants |
| Race/Ethnicity, Customized Other | 4 participants | 1 participants | 5 participants |
| Race/Ethnicity, Customized White | 97 participants | 74 participants | 171 participants |
| Region of Enrollment United States | 166 participants | 155 participants | 321 participants |
| Serum Chemistry: Creatinine | 1.0 mg/dL | 1.1 mg/dL | 1.06 mg/dL |
| Serum Chemistry: Lactate | 1.5 mg/dL | 1.6 mg/dL | 1.6 mg/dL |
| Serum Chemistry: Troponin I | 0.28 ng/ml | 0.31 ng/ml | 0.29 ng/ml |
| Sex: Female, Male Female | 59 Participants | 62 Participants | 121 Participants |
| Sex: Female, Male Male | 107 Participants | 93 Participants | 200 Participants |
| Steroids Administered Steroids Administered: No | 41 participants | 33 participants | 74 participants |
| Steroids Administered Steroids Administered: Yes | 125 participants | 122 participants | 247 participants |
| Vasopressor Score | 100 units on a scale | 16.0 units on a scale | 37 units on a scale |
| Ventricular Ejection Fraction | 0.6 proportion ejection fraction | 0.59 proportion ejection fraction | 0.6 proportion ejection fraction |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk |
|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 0 / 247 | 0 / 235 | 0 / 494 | 0 / 458 | 0 / 166 | 0 / 155 |
| serious Total, serious adverse events | 45 / 247 | 51 / 235 | 81 / 494 | 54 / 458 | 8 / 166 | 14 / 155 |
Outcome results
Number of Organs Recovered Per Donor
Number of organs recovered per organ donor
Time frame: At time of organ recovery, up to 1 day
Population: Subjects were organ donors enrolled in this multicenter study
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| No RIPC | Number of Organs Recovered Per Donor | 3.79 organs recovered per donor | Standard Deviation 1.73 |
| RIPC | Number of Organs Recovered Per Donor | 3.60 organs recovered per donor | Standard Deviation 1.84 |
Change in Creatinine Clearance
Change in creatinine clearance (mL/min by Cockcroft-Gault method) from before intervention to terminal value
Time frame: Subjects will be followed from admission to explantation, an average of 4.5 days
Population: Donors in whom two serum creatinine values (one before intervention and another after the initial intervention) are available.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| No RIPC | Change in Creatinine Clearance | 0 mL/min |
| RIPC | Change in Creatinine Clearance | 0 mL/min |
Change in Dynamic Compliance
Change in dynamic compliance of the lung from before intervention to terminal value Cdyn = Dynamic compliance; Vt = tidal volume; PIP = Peak inspiratory pressure (the maximum pressure during inspiration); PEEP = Positive End Expiratory Pressure: Cdyn= Vt/PIP - PEEP
Time frame: Subjects will be followed from admission to explantation, an average of 4.5 days
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| No RIPC | Change in Dynamic Compliance | 2.30 L/cm H20 |
| RIPC | Change in Dynamic Compliance | 1.20 L/cm H20 |
Change in P:F Ratio
Change in ratio of arterial oxygen pressure:fraction inspired oxygen ratio from before intervention to terminal value
Time frame: Subjects will be followed from admission to explantation, an average of 4.5 days
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| No RIPC | Change in P:F Ratio | 6.5 ratio |
| RIPC | Change in P:F Ratio | 0.05 ratio |
Change in Serum Lactate
Change in serum lactate levels (mg/dL) from before intervention to the final value
Time frame: Subjects will be followed from admission to explantation, an average of 4.5 days
Population: Donors in whom at least two serum lactate levels (one before and one after the initial intervention) were available
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| No RIPC | Change in Serum Lactate | 0.12 mg/dL |
| RIPC | Change in Serum Lactate | 0.20 mg/dL |
Change in Troponins
Change in serum troponin I (ng/mL) from before intervention to terminal value
Time frame: Subjects will be followed from admission to explantation, an average of 4.5 days
Population: Only donors in whom two troponin I values (one before intervention and another after the initial intervention) were available were included in this analysis
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| No RIPC | Change in Troponins | -0.04 ng/mL |
| RIPC | Change in Troponins | -0.09 ng/mL |
Change in Vasopressor Score
Changes in the following: Vasopressor usage, serum Lactate, Creatinine clearance, arterial oxygen pressure:fraction of inspired oxygen (P:F) ratios, Lung Compliance, Cardiac biomarkers, ejection fraction (EF) from 2-dimensional Echocardiogram. Here we will present data for the change in vasopressor use evaluated using a vasopressor score. A numerical score calculated for number and dose of Vasopressors in use. The score is calculated using the following formula (from Zuppa AF et. al.CRIT CARE MED 2004 Vol. 32 p 2318-2322): Vasopressor Score= (dopamine dose\[y=ug/kg/min x 1\]) + (dobutamine dose \[ug/kg/min\] x 1) + (epinephrine dose \[ug/kg/min\] x100) + (norepinephrine dose \[ug/kg/min\] x 100) + (phenylephrine dose \[ug/kg/min\] x 100). The range for our study was 0-4900 with higher doses indicating higher vasopressor use in the donor.
Time frame: Vasopressor score was determined before aortic cross clamp minus the value prior to the first intervention, an average of 19 hours
Population: Donors in whom vasopressor agent and dose were described in the OPO records before intervention and prior to aortic cross clamp.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| No RIPC | Change in Vasopressor Score | -15.60 units on a scale |
| RIPC | Change in Vasopressor Score | -6.00 units on a scale |
Delayed Graft Function (DGF) of Kidney Recipients.
DGF is defined as the need for dialysis within the first week post transplantation.
Time frame: 7 days post-transplant
Population: Kidney recipients of donors in each arm.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| No RIPC | Delayed Graft Function (DGF) of Kidney Recipients. | DGF: Yes | 45 participants |
| No RIPC | Delayed Graft Function (DGF) of Kidney Recipients. | DGF: No | 202 participants |
| RIPC | Delayed Graft Function (DGF) of Kidney Recipients. | DGF: Yes | 51 participants |
| RIPC | Delayed Graft Function (DGF) of Kidney Recipients. | DGF: No | 184 participants |
Number of Organs Transplanted Per Donor
Number of organs transplanted from each organ donor
Time frame: Within 24 hours of organ recovery
Population: Subjects were organ donors enrolled in this multicenter study
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| No RIPC | Number of Organs Transplanted Per Donor | 3.41 Organs transplanted from each donor | Standard Deviation 1.9 |
| RIPC | Number of Organs Transplanted Per Donor | 3.31 Organs transplanted from each donor | Standard Deviation 1.94 |
Pulsatile Perfusion Flow
Perfusate flow (mL/min) in machine perfused kidneys.
Time frame: Up to 24 hours of machine perfusion
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| No RIPC | Pulsatile Perfusion Flow | Flow at 1 hour, mL/min | 98.58 mL/min | Standard Deviation 32.41 |
| No RIPC | Pulsatile Perfusion Flow | 4 hours | 105.28 mL/min | Standard Deviation 23.75 |
| No RIPC | Pulsatile Perfusion Flow | 8 hours | 117.98 mL/min | Standard Deviation 28.86 |
| No RIPC | Pulsatile Perfusion Flow | 12 hours | 115.19 mL/min | Standard Deviation 20.07 |
| RIPC | Pulsatile Perfusion Flow | 12 hours | 106.36 mL/min | Standard Deviation 32.55 |
| RIPC | Pulsatile Perfusion Flow | Flow at 1 hour, mL/min | 89.42 mL/min | Standard Deviation 38.31 |
| RIPC | Pulsatile Perfusion Flow | 8 hours | 94.21 mL/min | Standard Deviation 32.64 |
| RIPC | Pulsatile Perfusion Flow | 4 hours | 104.03 mL/min | Standard Deviation 40.66 |
Pulsatile Perfusion Parameters
Perfusate resistance (mm Hg/mL/min) in machine perfused kidneys.
Time frame: Up to 24 hours of machine perfusion
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| No RIPC | Pulsatile Perfusion Parameters | Resistance at 1 hour, mL/min | 0.29 Resistance, mm Hg/mL/min | Standard Deviation 0.12 |
| No RIPC | Pulsatile Perfusion Parameters | Resistance at 4 hours, mL/min | 0.25 Resistance, mm Hg/mL/min | Standard Deviation 0.1 |
| No RIPC | Pulsatile Perfusion Parameters | Resistance at 8 hours, mL/min | 0.22 Resistance, mm Hg/mL/min | Standard Deviation 0.09 |
| No RIPC | Pulsatile Perfusion Parameters | Resistance at 12 hours, mL/min | 0.22 Resistance, mm Hg/mL/min | Standard Deviation 0.08 |
| RIPC | Pulsatile Perfusion Parameters | Resistance at 12 hours, mL/min | 0.29 Resistance, mm Hg/mL/min | Standard Deviation 0.22 |
| RIPC | Pulsatile Perfusion Parameters | Resistance at 1 hour, mL/min | 0.38 Resistance, mm Hg/mL/min | Standard Deviation 0.3 |
| RIPC | Pulsatile Perfusion Parameters | Resistance at 8 hours, mL/min | 0.33 Resistance, mm Hg/mL/min | Standard Deviation 0.23 |
| RIPC | Pulsatile Perfusion Parameters | Resistance at 4 hours, mL/min | 0.31 Resistance, mm Hg/mL/min | Standard Deviation 0.23 |
Six Month Hospital Free Survival of All Organ Recipients
Six month hospital-free survival was defined as the number of days recipients survived following the initial discharge after the transplant.
Time frame: 6 months post-transplant
Population: Recipients of all organs from donors enrolled in the two arms
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| No RIPC | Six Month Hospital Free Survival of All Organ Recipients | 172 days |
| RIPC | Six Month Hospital Free Survival of All Organ Recipients | 171 days |
Acute Kidney Rejection
Diagnosis of rejection as documented in the recipient records in the Scientific Registry of Transplant Recipients (SRTR).
Time frame: 6 months after kidney transplantation
Population: This outcome was examined in recipients of in SRTR that received kidneys from donors in the RIPNOD trial
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| No RIPC | Acute Kidney Rejection | Rejection: Yes | 17 participants |
| No RIPC | Acute Kidney Rejection | Rejection: No | 230 participants |
| RIPC | Acute Kidney Rejection | Rejection: Yes | 13 participants |
| RIPC | Acute Kidney Rejection | Rejection: No | 222 participants |
Death-Censored Kidney Graft Survival at 6, 12 and 24 Months
kidney graft survival censored for death with functioning graft
Time frame: Kidney graft survival was monitored from transplant date until retransplantation or death up to 2 years as in SRTR data file October 2015
Population: Included were kidneys transplanted alone or with pancreas. All kidney grafts transplanted from donors in the RIPNOD trial and in whom recipient records are available in SRTR were included in this analysis. Kidney graft loss is defined as loss of functioning graft or retransplantation during the 24 months post-transplant.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| No RIPC | Death-Censored Kidney Graft Survival at 6, 12 and 24 Months | Death censored kidney survival: 6 months | 94.2 percentage of participants |
| No RIPC | Death-Censored Kidney Graft Survival at 6, 12 and 24 Months | 12 months | 92.5 percentage of participants |
| No RIPC | Death-Censored Kidney Graft Survival at 6, 12 and 24 Months | 24 months | 87.4 percentage of participants |
| RIPC | Death-Censored Kidney Graft Survival at 6, 12 and 24 Months | Death censored kidney survival: 6 months | 99.1 percentage of participants |
| RIPC | Death-Censored Kidney Graft Survival at 6, 12 and 24 Months | 12 months | 96.8 percentage of participants |
| RIPC | Death-Censored Kidney Graft Survival at 6, 12 and 24 Months | 24 months | 96 percentage of participants |
Graft Survival
Kaplan-Meier estimates of 6, 12 and 24 months survival of all grafts
Time frame: Graft survival was monitored from transplant date until retransplantation or death up to 2 years as in SRTR data file October 2015
Population: All grafts transplanted from donors in the RIPNOD trial and in whom recipient records are available in SRTR were included in this analysis. Graft loss is defined as retransplantation or death during the 24 months post-transplant.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| No RIPC | Graft Survival | 6 months graft survival | 91.3 percentage of all grafts |
| No RIPC | Graft Survival | 12 months | 88.8 percentage of all grafts |
| No RIPC | Graft Survival | 24 months | 82.2 percentage of all grafts |
| RIPC | Graft Survival | 6 months graft survival | 94.6 percentage of all grafts |
| RIPC | Graft Survival | 12 months | 92.2 percentage of all grafts |
| RIPC | Graft Survival | 24 months | 87.8 percentage of all grafts |
Recipient Survival
Kaplan-Meier estimates of 6, 12 and 24 months survival of all recipients
Time frame: Recipient survival was monitored from transplant date until death up to 2 years as in SRTR data file October 2015
Population: All recipients of organs from donors in the RIPNOD trial and in whom recipient records are available in SRTR were included in this analysis
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| No RIPC | Recipient Survival | Recipient survival: 6 months | 92 percentage of participants |
| No RIPC | Recipient Survival | 12 months | 90.0 percentage of participants |
| No RIPC | Recipient Survival | 24 months | 84.4 percentage of participants |
| RIPC | Recipient Survival | Recipient survival: 6 months | 94.1 percentage of participants |
| RIPC | Recipient Survival | 12 months | 91.5 percentage of participants |
| RIPC | Recipient Survival | 24 months | 87.1 percentage of participants |